RandallE.MillikanMD

Oncology • Duluth, MN

Genitourinary Oncology, Hematologic Oncology

Staff Physician at Essentia Health

Join to view full profile

Dr. Millikan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Millikan's full profile

Already have an account?

Office
400 E 3RD ST ESSENTIA HEALTH DULUTH CLINIC
Duluth, MN 55805
Phone+1 218-786-3625

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1988 - 1991
University of Miami Leonard M. Miller School of MedicineClass of 1988

Certifications & Licensure

IL State Medical License 2022 - 2026
MN State Medical License 2013 - 2024
WA State Medical License 2020 - 2023
OR State Medical License 2020 - 2022
UT State Medical License 2019 - 2022
TX State Medical License 1994 - 2013
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2006-2008
America's Top Doctors for Cancer Castle Connolly, 2005-2007

Clinical Trials

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Start of enrollment: 1996 Aug 01
Completed
Phase 3
Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer Start of enrollment: 1997 Dec 01
Completed
Phase 2
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium Start of enrollment: 2001 Jul 01
Completed
Phase 2
BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets Start of enrollment: 2009 Mar 01
Completed
Phase 1
A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity Start of enrollment: 2012 May 24
Terminated
Phase 1
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Start of enrollment: 2016 May 11
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

11 citations
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate...
Farshid Dayyani, Amado J. Zurita, Graciela M. Nogueras-Gonzalez, Rebecca Slack, Randall E. Millikan
BMC Cancer. 2016-09-06
36 citations
A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers.
Arlene O. Siefker-Radtke, Xin Qiao Zhang, Charles C. Guo, Yu Shen, Kathleen F. Pirollo
Molecular Therapy. 2016-08-01
213 citations
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chem...
David J. McConkey, Woonyoung Choi, Yu Shen, I. Ling Lee, Sima P. Porten
European Urology. 2016-05-01

Other

Experimental systemic therapy of metastatic bladder cancer
Millikan RE
http://www.uptodate.com/contents/experimental-systemic-therapy-of-metastatic-bladder-cancer
UpToDate, Wolters Kluwer Health - 2012-09-25

Grant Support

Neoadjuvant Therapy For Advanced Bladder CancerNational Cancer Institute1996–1999